© 2022 MJH Life Sciences and Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
© 2022 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
Marc Matrana, MD discusses the case of a man with mCSPC and reviews the current state of the mCSPC treatment landscape including both approved and emerging treatment options.
August 30th 2022
Marc Matrana, MD shares his perspective on an mCSPC patient case, focusing on the typical trajectory for patients with biochemical recurrence.
A prostate cancer expert shares a brief overview of available first-line therapy options for patients with mCSPC.
Clinical insights concerning the selection of effective treatment approaches for patients with mCSPC with comments on the study design and results of the TITAN study.
Discussion centered around androgen receptor inhibition/androgen synthesis inhibition and comparison of available, approved options for each.
An experienced clinician expands on effective strategies for monitoring patients with mCSPC during and after treatment and reviews patient expectations following disease progression.
Insight on recent developments and emerging options in the mCSPC treatment landscape.
Dr. Marc Matrana closes the discussion with considerations for clinicians on treating patients with prostate cancer.